Active substance
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| RUKOBIA | EQ 600MG BASE | tablet, extended release · oral | VIIV HLTHCARE | Prescription | 2 Jul 2020 |
Rukobia, in combination with other antiretrovirals, is indicated for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| RUKOBIA | 02520869 | 600 MG | TABLET (EXTENDED-RELEASE) · ORAL | VIIV HEALTHCARE ULC |
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | RUKOBIA ER 600 MG TABLET | $156.83623 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.